Healthcare ETFs weakened Wednesday after Abbot Laboratories (NYSE: ABT) slipped on a revenue miss and revealed an uninspiring forecast for the first quarter of the new year.

The Health Care Select Sector SPDR ETF (NYSEArca: XLV) fell 0.3% on Wednesday while the S&P 500 was 0.1% lower.

Abbot Laboratories’ quarterly revenue fell short of expectations due to lower sales of generic drugs in the emerging markets, Reuters reports.

ABT shares declined 2.3% Wednesday after the announcement. ETFs with heavier tilts toward ABT were also dragged down by the report, with the iShares US Medical Devices ETF (NYSEArca: IHI) down 0.5% and First Trust Nasdaq Pharmaceuticals ETF (NasdaqGM: FTXH) 0.6% lower.

Furthermore, the healthcare company projected current-quarter earnings below analysts’ estimates. Some anticipated the stronger U.S. dollar to hurt profits as a large portion of their revenue comes from overseas sources.

“Some may look at these results and guidance as nothing too special, especially since Abbott had a lower tax rate than what we were anticipating, which helped this quarter’s results,” Edward Jones analyst John Boylan said.

Subscribe to our free daily newsletters!
Please enter your email address to subscribe to ETF Trends' newsletters featuring latest news and educational events.